BioCentury | Jan 5, 2021
Product Development

Crucible of COVID, ahoy 2021 & cancer deal trends: a BioCentury podcast

...Tokyo:4502; NYSE:TAK) and Haumann is CMO of Theravance Biopharma Inc....
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...Ltd. (Tokyo:4502; NYSE:TAK) and Haumann is CMO at Theravance Biopharma Inc....
...than purifying proteins. C. Simone Fishburn Takeda Pharmaceutical Co. Ltd. Theravance Biopharma Andy...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...clinic to treat COVID-19. New entries this week include therapies from Evelo Biosciences Inc. (NASDAQ:EVLO), Theravance Biopharma Inc....
...ambrisentan Forxiga (Brand), Farxiga (Brand), BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Losmapimod (DUX4 inhibitor) TD-0903 PL8177 BARDA Evelo Biosciences Inc. Theravance Biopharma Inc. Fulcrum...
BioCentury | Apr 9, 2020
Product Development

Pfizer’s COVID-19 push: antiviral candidate identified as anti-inflammatory Xeljanz starts trial

...other institutions. COVID-19 clinical trials for at least two other JAK inhibitors have been announced. Theravance Biopharma Inc....
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...Theravance, Adverum, Moderna price follow-ons With a $148.5 million offering, Theravance Biopharma Inc. (NASDAQ:TBPH) was among at least...
...CXC chemokine receptor 4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...Theravance gains $10M upfront in Pfizer deal Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide...
...Programmed cell death 1 ligand; PSMA (FOLH1; GCPII) - Prostate-specific membrane antigen Hongjiang Li, Staff Writer KN035, 3D-2-02-0015 Theravance Biopharma Inc. Pfizer...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...strategic portfolio advice and review committee. Suliman was SVP of corporate development and strategy at Theravance Biopharma Inc....
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...and COO, as well as CSO. Prior to BlackThorn’s founding, he was executive director at Theravance Biopharma Inc....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc....
Items per page:
1 - 10 of 109
BioCentury | Jan 5, 2021
Product Development

Crucible of COVID, ahoy 2021 & cancer deal trends: a BioCentury podcast

...Tokyo:4502; NYSE:TAK) and Haumann is CMO of Theravance Biopharma Inc....
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...Ltd. (Tokyo:4502; NYSE:TAK) and Haumann is CMO at Theravance Biopharma Inc....
...than purifying proteins. C. Simone Fishburn Takeda Pharmaceutical Co. Ltd. Theravance Biopharma Andy...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...clinic to treat COVID-19. New entries this week include therapies from Evelo Biosciences Inc. (NASDAQ:EVLO), Theravance Biopharma Inc....
...ambrisentan Forxiga (Brand), Farxiga (Brand), BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Losmapimod (DUX4 inhibitor) TD-0903 PL8177 BARDA Evelo Biosciences Inc. Theravance Biopharma Inc. Fulcrum...
BioCentury | Apr 9, 2020
Product Development

Pfizer’s COVID-19 push: antiviral candidate identified as anti-inflammatory Xeljanz starts trial

...other institutions. COVID-19 clinical trials for at least two other JAK inhibitors have been announced. Theravance Biopharma Inc....
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...Theravance, Adverum, Moderna price follow-ons With a $148.5 million offering, Theravance Biopharma Inc. (NASDAQ:TBPH) was among at least...
...CXC chemokine receptor 4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...Theravance gains $10M upfront in Pfizer deal Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide...
...Programmed cell death 1 ligand; PSMA (FOLH1; GCPII) - Prostate-specific membrane antigen Hongjiang Li, Staff Writer KN035, 3D-2-02-0015 Theravance Biopharma Inc. Pfizer...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...strategic portfolio advice and review committee. Suliman was SVP of corporate development and strategy at Theravance Biopharma Inc....
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...and COO, as well as CSO. Prior to BlackThorn’s founding, he was executive director at Theravance Biopharma Inc....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc....
Items per page:
1 - 10 of 109